We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Sequencing Study Finds Clues to Determining Causes of Lethal Epidemics

By LabMedica International staff writers
Posted on 19 Feb 2010
A team of collaborating scientists has sequenced almost 100 full genomes from three successive epidemics of flesh-eating bacteria. More...
This has resulted in the first precise explanation of the biologic events contributing to deadly epidemics of severe infection. This method can be used to track and help prevent epidemics in the future.

The scientists involved in the project were from at the Methodist Hospital Research Institute (Houston, TX, USA), the Broad Institute (Boston, MA, USA), Mount Sinai Hospital (Toronto, ON, Canada) and the Ontario Agency for Health Protection and Promotion (OAHPP). Results of this research, funded by the U.S. National Institutes of Health (Bethesda, MD, USA) and The Methodist Hospital Research Institute, appear in a study published online January 21, 2010, in Proceedings of the [U.S.] National Academy of Sciences (PNAS).

"The extensive full-genome data provide us with new clues about the bacteria's ability to take advantage of vulnerabilities in the person who has contracted the bacteria,” said Dr. James M. Musser, codirector of the Methodist Hospital Research Institute and the senior, corresponding author of the study. "With this type of unique molecular portrait of the bacterial pathogen, we can more effectively develop drugs to prevent the spread of epidemics and construct novel diagnostic and treatment strategies.”

"Until now, it has been a mystery why sometimes we see two opposing types of infection in patients who appear to have the same strain of flesh-eating bacteria,” said Dr. Donald Low, chief microbiologist at Mount Sinai Hospital, medical director of the OAHPP Public Health Laboratories and one of the authors of the study. "In some cases, patients suffer from a devastating infection of tissue and muscle requiring extensive surgery, and, other patients present with a skin infection readily treated with antibiotics. Now, we understand in part why this happens.”

Understanding the full molecular architecture of bacterial epidemics has been a long-sought goal of infectious disease research, Dr. Low noted. Genetics and evolution research has long been hobbled by the lack of comprehensive genome-wide markers. The recent advent of massively parallel DNA sequencing techniques now permits full-genome sequences to be generated quickly. This opens an avenue to answering longstanding but previously economically costly questions in all areas of biomedical research, including bacterial epidemics.

Dr. Musser's lab, working closely with collaborators at Mount Sinai Hospital, the Ontario Provincial Public Health Laboratory, the Broad Institute, and Sequenom (San Diego, CA, USA) utilized short-read-length DNA sequencing combined with mass spectroscopy analysis of single nucleotide polymorphisms (SNPs), to study the molecular pathogenomics of three successive epidemics of invasive infections involving 344 serotype M3 group A Streptococcus in Ontario, Canada.

Sequencing the genome of 95 strains from the three epidemics, coupled with analysis of 280 biallelic SNPs in all 344 strains, revealed an unexpectedly complex population structure composed of a dynamic mixture of unique clonally related complexes. On average, each strain was differentiated from one another by only 49 SNPs and 11 insertion-deletion events (indels) in the core genome.

The investigators revealed that each strain has a distinct genome sequence, which brings unparalleled ability to monitor strain spread. The extensive full-genome data permitted the investigators to identify genes with unusually high rates of genetic variation, thereby providing new insights into selective forces at work in the host.

Related Links:
Methodist Hospital Research Institute
Broad Institute
Mount Sinai Hospital
Ontario Agency for Health Protection and Promotion
Sequenom



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.